Top 50 Cell Line Development

Cytena develops single-cell printing technology and automated solutions for cell line development, enabling the efficient production of stable cell lines for therapeutic applications. Their systems streamline workflows for biopharmaceutical companies, reducing the time and cost associated with developing biologics while ensuring compliance with regulatory standards.

The startup manufactures immune clinical cells to facilitate cell therapy development, utilizing specialized software tools for the design, production, and analysis of these therapies. Their integrated approach combines a dedicated manufacturing facility and a team of experts, enabling researchers to expedite the delivery of effective cell therapies to patients.

64x Bio develops a high throughput genome engineering platform that accelerates the discovery of optimized mammalian cell lines for cell and gene therapies. This technology enables pharmaceutical and biotechnology companies to efficiently design and manufacture next-generation therapeutics, addressing the challenges of traditional cell line development.

Great Bay Bio develops biopharmaceuticals using its AI-enabled platforms, AlfaCell and AlfaMedX, which streamline cell line development and optimize cell culture media. This technology reduces the time and complexity of producing high-yield, stable cell lines, addressing inefficiencies in traditional biologics development.

Bit.bio develops a cell coding platform that utilizes deterministic programming to create and manufacture any human cell type with precision and scalability. This technology addresses the need for consistent and reliable cell production for research and therapeutic applications, enabling the development of next-generation treatments.

The startup operates a cell therapy research and manufacturing platform that enhances process control and scalability in autologous cell and gene therapy bioprocessing. By enabling parallel execution of cell culture conditions, the platform reduces manufacturing costs while improving efficiency in process development.

Trailhead Biosystems develops iPSC-derived human cells for drug discovery and cell-based therapies, utilizing the High-Dimensional Design of Experiments (HD-DoE) platform to optimize cell growth and differentiation. Their products, such as the TrailBio® Endothelial Cell Kit and Pre-Myelinating Oligodendrocyte Kit, provide reliable solutions for vascular biology research and myelination studies, addressing the need for precise cellular models in regenerative medicine.

Asimov develops a platform that integrates synthetic biology, biophysical simulations, and machine learning to engineer mammalian cell lines for the production of biologics and gene therapies. This technology enables healthcare companies to optimize the design and manufacturing processes of genetic circuits, improving efficiency and scalability in therapeutic applications.

Opo Bio specializes in cell line development for the cultivated meat industry, providing a multi-species and multi-cell type bank that supports large-scale cell culture. By supplying optimized livestock cells, Opo Bio enables producers to enhance cultivation efficiency and reduce production costs for cultivated meat products.

The startup provides contract development services for preclinical and clinical drug projects, specializing in the supply of ready-to-inject adipose-derived allogeneic stem cells. This offering enables healthcare companies to lower manufacturing costs and improve the affordability of cell therapies.

The startup develops machine-learning tools to design cell factories capable of producing a wide range of products, including food, fabrics, and medicines. By simplifying the complex process of cellular manufacturing, the company aims to replace traditional farms and factories, promoting a more sustainable production model.

The startup develops a DNA integration platform that enhances the engineering of cell lines for gene and cell therapies, specifically targeting the production of recombinant adeno-associated virus vectors. By improving viral vector yield and efficacy, the company enables biopharmaceutical firms to produce more effective therapies for serious diseases.

Celleo Biotech develops intelligent production systems for the manufacture of cell and gene therapies, enabling scalable and compliant GMP processes tailored to diverse therapeutic modalities. This technology addresses the challenge of limited access to effective cell therapies by facilitating broader production capabilities for biotherapeutics, ultimately improving patient outcomes.

Mytos is developing a fully automated platform for the manufacture of any human cell type, utilizing advanced robotics and software to streamline cell culture processes. This technology addresses the challenges of contamination and human error in cell production, enabling consistent, high-quality output at a scale that allows one technician to achieve the productivity of ten scientists working manually.

CellRev specializes in process intensification for cell manufacturing through advanced bioprocessing techniques that enhance yield and efficiency. The company reduces high production costs and lengthy timelines in biomanufacturing, facilitating faster and more cost-effective development of cell-based therapies.

CellRep develops cell reprogramming strategies to enhance T cell functionality, increasing their therapeutic potential for cancer and chronic conditions. The company provides an end-to-end pipeline from target discovery to preclinical validation, enabling more effective cell therapies for patients.

Avigen is developing a platform to identify highly effective immune cells for use in cellular immunotherapies. This technology aims to accelerate the development of new therapies by pre-selecting potent cells, reducing risks and streamlining the process.

Center for Breakthrough Medicines is a contract development and manufacturing organization specializing in cell and gene therapies, providing integrated services for drug substance and product across all phases of the product lifecycle. The company addresses the need for efficient and precise manufacturing processes in the rapidly evolving advanced therapy sector, enabling faster delivery of life-saving treatments to patients.

Core Biogenesis utilizes proprietary plant-based bioproduction technologies to manufacture animal-free, endotoxin-free recombinant growth factors and cytokines for cell culture applications. This approach enhances the consistency and reproducibility of cell cultures, addressing the critical issue of endotoxin contamination in biomanufacturing processes.

The startup develops AI-driven live-cell imaging technology to predict and optimize stem cell differentiation, enabling the scalable manufacture of any cell or tissue in the body. This approach addresses the need for effective stem cell-based therapies for chronic diseases, facilitating data-driven drug development and improving patient outcomes.

The startup provides bioprocessing solutions that enhance the development and manufacturing of biologic therapies through advanced cell culture and purification techniques. By streamlining these processes, the company enables biopharmaceutical and contract manufacturing organizations to accelerate the delivery of safe therapies to patients.

Cell Bauhaus develops a virtual cell technology platform that enables the computer-aided design and simulation of living systems, allowing researchers to optimize genetic constructs and cellular behavior before laboratory experimentation. This approach significantly reduces the time and cost associated with bringing synthetic biology products to market by minimizing trial and error in the development process.

Mekonos develops a proprietary cell-engineering platform that utilizes microfluidic technology to facilitate the creation of cell therapies on a chip. This approach enables precise manipulation of cellular environments, improving the efficiency and scalability of therapeutic development.

Livestock Labs develops genetically engineered cell lines specifically for the cultivated meat industry, utilizing genetic engineering, data analytics, and machine learning to create stable and robust cell lines. Their offerings significantly reduce production costs and time for meat producers and research institutions, while ensuring optimal growth, flavor, and nutrition in cultivated meat products.

Pluristyx develops induced pluripotent stem cells (iPSCs) and offers gene editing technologies, including their proprietary FailSafe® edit, to enhance the manufacturing process of cellular therapies. The company addresses challenges in the development and commercialization of regenerative medicine by providing end-to-end support and expertise throughout the product lifecycle.

Deco Labs develops enabling technologies for cellular agriculture, focusing on cell line development, genetic engineering, and bioprocess design to enhance production efficiency. The startup addresses cost, scale, and quality challenges in the industry by optimizing media formulation and biomaterial development.

BrainXell specializes in producing high-purity, iPSC-derived human neurons, astrocytes, and microglia for research and drug discovery in central nervous system disorders. The company provides customizable cell lines in various quantities, enabling researchers to advance their studies with precise, patient-derived cellular models.

The startup specializes in customizing and packaging secretomes as conditioned media to enhance cell growth in human and cell culture applications. This approach provides a reliable source of growth factors and signaling molecules, addressing the challenge of inconsistent cell culture environments.

This biotechnology company programs cell metabolism to optimize biomanufacturing processes. They use metabolic modeling and minimal data to design custom cell culture media, enabling efficient production of advanced therapies.

The startup develops automated microbioreactors that leverage microtechnology to enhance precision in biochemical processes. This technology improves scalability and reproducibility in bioprocessing, leading to more efficient production of biological materials.

iXCells Biotechnologies specializes in preclinical drug discovery by providing disease-relevant cellular models, including iPSC-derived cell products and custom genome editing services. Their offerings enable researchers in academia and the pharmaceutical industry to conduct high-quality functional assays and accelerate the understanding of complex diseases.

The startup develops cell-related therapeutics utilizing induced pluripotent stem cells through cardiomyocyte differentiation and myocardial purification methods with small-molecule compounds. This research enables pre-clinical validation for improved regenerative medicine treatments and cell transplantation procedures.

The startup develops biopharmaceuticals by creating production cell lines and formulating drug substances and finished drugs tailored to patient needs. This approach enables the delivery of personalized medicines, addressing the lack of access to customized treatment options for patients.

Cellevolve Bio develops and commercializes cell therapies to treat various diseases by utilizing advanced cellular engineering techniques. The company focuses on addressing the limitations of current treatment options, providing targeted and effective solutions for patients with unmet medical needs.

Celltrio manufactures automated cell culturing systems and biobanking solutions that enhance the efficiency and accuracy of biological sample management. Their technology addresses the challenges of manual handling and storage of cell cultures, reducing contamination risks and improving data integrity in research and clinical applications.

The startup provides chemically defined cell culture media and supplements that enhance cell growth performance beyond traditional serum and Essential 8. This offering addresses issues of batch-to-batch variability, contamination risks, and high costs associated with serum, facilitating the advancement of cellular-based therapies in clinical trials and research.

The startup develops optimized parental cells for the production of stem cell exosomes, which have superior proliferation and secretion capabilities. This technology enables mass production of exosomes, providing a scalable solution for targeting incurable diseases.

The startup has developed a single-use, end-to-end autologous cell manufacturing platform that enables bedside production of life-saving therapies. This system enhances quality assurance, reduces time to market, and lowers costs, ensuring greater availability of advanced cell therapies for patients.

The startup specializes in cell encapsulation technology that enhances the efficiency of cell mass production for engineering applications. This technology enables clients to utilize cells effectively across various domains, from research to clinical use, by providing a reliable method for handling and processing cells.

BioLamina provides human recombinant laminin proteins that mimic the native extracellular matrix for improved cell culture. These biologically relevant substrates support robust cell expansion, differentiation, and maintenance, enhancing cell functionality and reproducibility for regenerative medicine and cell therapy development.

The startup specializes in stem cell engineering to produce authentic human neurons for modeling neurological diseases and dysfunctions. This technology enables medical professionals to enhance the development of novel therapeutics targeting neurological and neurodegenerative conditions.

The startup operates a cell biobank that provides a diverse range of African species cell lines for the foodtech and biomedical sectors. This resource enables the development of sustainable biotechnological solutions that enhance biodiversity and improve global food security.

ChemT Biotechnology is pioneering the use of small molecules to enhance the manufacturing process of immune cell therapies, achieving a 5-10x increase in yield while improving product quality. This approach addresses the high production costs and inconsistent quality that currently plague the cell and gene therapy industry.

CELLphenomics specializes in the development and cultivation of patient-derived 3D cell culture models (PD3D®) from solid tumor tissues, enabling high-throughput efficacy testing and personalized toxicity profiling for drug discovery. Their extensive biobank of over 600 complex in vitro models, combined with clinical and molecular data, provides researchers with biologically relevant tools to assess treatment sensitivity and resistance in cancer therapies.

Myoridge specializes in the development of high-purity myocardial cells with optimized culture media, enhancing drug response rates for cardiac research and therapies. The company addresses the challenge of inefficient cell culture processes in regenerative medicine by providing tailored media solutions and comprehensive support for cell-based product development.

The startup develops a machine learning platform that utilizes a proprietary non-GMO bovine stem cell line to enhance cell culture conditions for alternative meat and dairy production. This technology enables companies in the cultivated meat sector to efficiently scale up production by sourcing functional ingredients tailored to their specific needs.

The startup develops cell biology platforms that enhance live cell microscopy through advanced techniques such as serum-free cell culture and surface chemistry biochips. This technology enables researchers to monitor molecular communications in cells, providing critical insights into disease progression and recovery processes.

Cellex provides automated bioreactor systems for advanced cell culture and tissue engineering. Their BioAxFlow bioreactor ensures uniform cell seeding and distribution on scaffolds through a continuous perfusion system, improving cell viability and reproducibility in 3D tissue development.

The startup develops curative cell therapy medicines utilizing directed differentiation, forward programming, and tissue environment engineering to treat life-threatening metabolic and respiratory diseases. By transforming patient cells, the company aims to restore normal function and improve quality of life for individuals affected by these conditions.

This startup engineers stem cells to control their differentiation into specific cell types for research and therapeutic applications. By precisely manipulating stem cell fate, they aim to provide customized cell lines for drug discovery, disease modeling, and regenerative medicine.